CHICAGO, IL (January 19, 2021) – Sheridan Capital Partners (“Sheridan”) announced today the closing of its oversubscribed second buyout fund, Sheridan Capital Partners Fund II, L.P. (together with its parallel fund, “Fund II” or the “Fund”), at its hard cap of $300 million in Limited Partner commitments, more than double the size of its predecessor. Sheridan is focused on making investments in lower middle market companies in recession resistant, non-discretionary markets within the healthcare industry. The Fund will continue Sheridan’s strategy of making control investments in North American founder-owned businesses with $3-15 million of EBITDA.
“We are extremely pleased with the support provided by our investors, both new and existing, which allowed us to exceed our target and hit our hard cap for Fund II in a competitive and challenging fundraising environment,” stated Jonathan Lewis, Founder & Partner of Sheridan. “We would also like to thank our placement agent Sixpoint Partners for their partnership throughout the fundraise.”
Investors in Fund II include a diversified mix of insurance companies, fund-of-funds, family offices and asset managers, among other limited partners, located across North America, Europe and the Middle East.
Sean Dempsey, Partner of Sheridan, said, “The entire Sheridan team is excited to continue its strategy of partnering with high quality, lower middle market healthcare businesses and executives, leveraging our sector expertise and proven operating playbook to accelerate growth across our portfolio both organically and through acquisitions to build market leading companies.”
Sixpoint Partners served as the exclusive global placement agent for Fund II and Kirkland & Ellis LLP served as fund counsel and legal advisor.
Sheridan Capital Partners is a Chicago-based healthcare private equity firm that focuses on lower middle market buyouts and growth equity in the U.S. and Canada. Sheridan partners with companies in the verticals of providers and provider services, healthcare IT and outsourced services, and consumer health and medical products, bringing strategic resources to accelerate growth, build enduring value, and achieve strong results.